Table 3 Postoperative outcomes
From: Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures
Characteristic | Arista® AH (n = 103) | Control (n = 137) | p-value |
|---|---|---|---|
CT output 48 hrs postop (mL) | 1594 ± 949 | 2112 ± 1437 | <0.001 |
PRBCs 48 hrs postop (units) | 2.4 ± 2.5 | 4.0 ± 5.1 | <0.001 |
-Patients received 1–2 units | 35 (34%) | 56 (41%) | -- |
-Patients received ≥3 units | 34 (33%) | 49 (36%) | -- |
ICU platelets 48 hrs postop (units) | 1.2 ± 2.3 | 1.8 ± 3.4 | 0.10 |
ICU FFP 48 hrs postop (units) | 1.2 ± 2.6 | 1.9 ± 3.7 | 0.12 |
ICU stay (median days) | 8(range 2–37) | 9(range 2–57) | 0.08 |
30 day mortality, (%) | 17.5% | 16.1% | NS |